Based on our research, we believe that the common denominator underlying each intestinal microbiome is a network of interconnected, interdependent and metabolic functions that are essential for the host and the microbiome.
See more about our perspective on microbiome function
PharmaBiome has developed unique technologies to access the entire range of intestinal bacteria for the design and production of function-based consortia at scale.
Read about our differentiated technologies
We are a pre-clinical stage spinoff from the ETH Zurich, combining key expertise in microbiology, biotechnology and the molecular disease mechanisms that involve the microbiome.
See the expertise of our board, advisors and operational team
We unlock the therapeutic potential of the microbiome through our deep understanding of microbial function, host-microbiome interactions and disease-specific dynamics, enabling us to discover and develop therapeutics and bring the hope for cure to patients.
We strive to become the leading global experts in the development of bacterial consortia based on mixed cultures. Our mission is to unlock the therapeutic potential of the microbiome through a deep understanding of its function and the disease-specific dynamics.
Research informs our belief that the smallest relevant biological unit is the function, delivered by intestinal bacteria, and not the bacterial strain. These bacteria interact in a complex functional network to achieve a metabolically balanced microbiome.more about function
The human microbiome fulfills a variety of functions. Each function is encoded in a set of bacteria that each have several functions under different circumstances. A bacterial consortium needs to be versatile, balanced and cover all the essential functions.more about science
We take a bottom-up approach and engineer bacterial consortia based on their metabolic interactions. Our deep understanding of function drives the selection of individual strains to be assembled and co-cultured with our groundbreaking technology.more about our approach
Microbiome therapies go beyond FMT and are targeted to introduce a functionality. Starting with the biology of a specific disease, a tailored consortium of bacteria is mixed and co-cultured to reverse a dysbiosis.more about therapies
PharmaBiome announces the election of two new board members. To brdige to a planned Series A financing, CHF 1.75 Mio were raised.read more
Our pioneering efforts are awarded a price! PharmaBiome AG is proud to be a finalist of the ZKB Pionierpreis 2020.read more
We are proud to receive this prestigious grant and are eager to turn our learnings from this great program into action.read more
PharmaBiome AG is among the Top Ten startups selected for the ZKB Pionierpreis 2020read more
PharmaBiome is proud to be among the 15 companies selected for the BaseLaunch Accelerator Program.read more
PharmaBiome is one of the winners at the 2019 De Vigier Foundation Awards, recognizing its leadership in developing microbiome based therapies.read more
For IBD Day 2019 we have supported a video artist who sheds light on the unmet medical need. Addressing the microbiome may open the door to a curative therapy.read more
PharmaBiome was awarded with the seal of excellence from the European Commission Horizon2020 programm …read more
PharmaBiome founder and leader Tomas de Wouters recognized …read more
Philip Hemme from Labiotech interviews Dr. Tomas de Wouters about our unique approach to functioning bacterial mixes …read more